樂普生物-B(02157.HK)授權T細胞銜接器技術 首付款1000萬美元+最高8.5億美元里程碑付款
格隆匯8月1日丨樂普生物-B(02157.HK)發佈公告,2025年8月1日,公司(作爲許可人及轉讓人)透過訂立知識產權轉讓與許可協議及購股協議,與Excalipoint(作爲被許可人及受讓人)就對外授出及╱或轉讓與集團專有的T細胞銜接器TOPAbody平臺所開發的兩項臨牀前資產有關的若幹知識產權訂立一項許可交易。
根據知識產權轉讓與許可協議及購股協議,並在其條款及條件的規限下,Excalipoint將獲得在全球範圍內開發及商業化目標產品的獨家權利,作爲對價,公司將收取(i)總額爲1,000萬美元的現金首付款,及Excalipoint開曼向公司全資附屬公司Innocube發行的普通股(佔Excalipoint開曼經擴大發行股本的10%),(ii)總額最高爲8.475億美元的研發及商業里程碑付款,及(iii)按低個位數百分比至中個位數百分比分級計算的銷售特許權使用費。
此外,集團有權委任一名董事加入Excalipoint開曼董事會。在進行上述許可交易的同時,Excalipoint開曼將進行A輪融資,其中紅杉中國、元生創投及杏澤資本(作爲聯合牽頭A輪投資者)所管理的基金,連同其他A輪投資者(包括五源資本、凱風創投、冪方健康基金及弘毅投資所管理的基金)將根據購股協議的條款及條件向Excalipoint開曼合共投資4,100萬美元。
董事會認爲,許可交易及Excalipoint開曼A輪融資的成功,充分挖掘公司現有產品管線和技術的商業價值,推動公司實現全球化戰略佈局。同時,該交易亦有助於公司進一步聚焦於推動下一代ADC藥物及免疫腫瘤雙╱三特異性抗體的研發戰略,加快後期產品的商業化。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.